Published in J Bone Miner Res on July 01, 2009
Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int (2010) 1.17
Do bisphosphonates affect bone healing? A meta-analysis of randomized controlled trials. J Orthop Surg Res (2014) 1.07
Current and future treatment options in osteoporosis. Eur J Clin Pharmacol (2011) 0.98
Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int (2010) 0.94
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int (2012) 0.91
Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging (2013) 0.89
Parameters Pointing at an Increased Risk for Contralateral Hip Fractures: Systematic Review. Geriatr Orthop Surg Rehabil (2016) 0.84
Effect of osteoporosis medications on fracture healing. Osteoporos Int (2015) 0.83
Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int (2014) 0.82
Short-term changes in body composition after surgical repair of hip fracture. Age Ageing (2013) 0.81
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther (2010) 0.81
Seven years' experience with alendronate in postmenopausal Japanese women with osteoporosis. Ther Clin Risk Manag (2010) 0.79
Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int (2017) 0.78
Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskelet Dis (2010) 0.78
[Osteoporotic treatment options in geriatric patients]. Z Gerontol Geriatr (2012) 0.77
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest (2016) 0.77
Brigham fracture intervention team initiatives for hospital patients with hip fractures: a paradigm shift. Int J Endocrinol (2010) 0.77
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis. Ther Clin Risk Manag (2010) 0.77
Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study. Clin Interv Aging (2014) 0.77
Subgroup variations in bone mineral density response to zoledronic acid after hip fracture. J Bone Miner Res (2014) 0.76
Influence of Early Bisphosphonate Administration for Fracture Healing in Patients with Osteoporotic Proximal Humerus Fractures. Clin Orthop Surg (2016) 0.76
Effects of Zoledronate on Mortality and Morbidity after Surgical Treatment of Hip Fractures. Adv Orthop (2016) 0.75
Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis. Patient Prefer Adherence (2010) 0.75
Effect of bisphosphonate initiation at week 2 versus week 12 on short-term functional recovery after femoral neck fracture: a randomized controlled trial. Arch Osteoporos (2017) 0.75
[Proximal femoral fractures in the elderly]. Z Gerontol Geriatr (2015) 0.75
[Co-management in geriatric traumatology]. Orthopade (2015) 0.75
Challenges to prevent secondary fractures in patients with hip fractures in Joetsu Myoko, Japan through the increased use of osteoporosis treatment and collaboration with family doctors. J Bone Miner Metab (2016) 0.75
[Osteoporosis: therapy in interface management]. Wien Med Wochenschr (2013) 0.75
Surgical trauma and low-dose methylprednisolone modulate the severity of the acute-phase response induced by zoledronic acid infusion. Exp Ther Med (2017) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med (2002) 6.37
Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med (2010) 6.13
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 4.63
Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med (2010) 4.24
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab (2008) 3.67
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40
Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int (2008) 3.34
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis (2002) 2.67
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: a randomized controlled pilot study. J Bone Miner Res (2003) 2.47
The effect of comorbid illness on receipt of cancer screening by older people. J Am Geriatr Soc (2002) 2.42
Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med (2003) 2.41
A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab (2005) 2.30
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol (2011) 2.28
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc (2010) 2.19
Quantifying data quality for clinical trials using electronic data capture. PLoS One (2008) 2.19
Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med (2004) 2.18
Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res (2004) 2.15
[The vitamin D status of the Danish population needs to be improved]. Ugeskr Laeger (2005) 2.07
Androgens and bone. Endocr Rev (2004) 2.06
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab (2010) 2.01
Hemiarthroplasty or internal fixation for intracapsular displaced femoral neck fractures: randomised controlled trial. BMJ (2007) 1.98
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int (2003) 1.97
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone (2007) 1.94
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord (2006) 1.85
Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD. J Clin Oncol (2006) 1.84
Mechanisms of anterior cruciate ligament injury in World Cup alpine skiing: a systematic video analysis of 20 cases. Am J Sports Med (2011) 1.83
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2014) 1.78
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res (2008) 1.78
Randomized trial to improve fracture prevention in nursing home residents. Am J Med (2007) 1.75
The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther (2005) 1.72
Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry (2010) 1.72
Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol (2009) 1.70
Cemented versus uncemented hemiarthroplasty for displaced femoral neck fractures. Clin Orthop Relat Res (2009) 1.70
Diagnosis and management of vertebral fractures in elderly adults. Am J Med (2002) 1.68
Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol (2012) 1.65
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother (2003) 1.61
Effect of low-intensity pulsed ultrasound on the cartilage repair in people with mild to moderate knee osteoarthritis: a double-blinded, randomized, placebo-controlled pilot study. Arch Phys Med Rehabil (2012) 1.60
Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J Sex Med (2013) 1.59
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
Risk factors for total hip replacement due to primary osteoarthritis: a cohort study in 50,034 persons. Arthritis Rheum (2002) 1.58
Frailty and sexual health in older European men. J Gerontol A Biol Sci Med Sci (2012) 1.58
Frailty in relation to variations in hormone levels of the hypothalamic-pituitary-testicular axis in older men: results from the European male aging study. J Am Geriatr Soc (2011) 1.57
Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol (2008) 1.55
Sagittal plane gait characteristics in hip osteoarthritis patients with mild to moderate symptoms compared to healthy controls: a cross-sectional study. BMC Musculoskelet Disord (2012) 1.55
Physical activity as a preventative factor for frailty: the health, aging, and body composition study. J Gerontol A Biol Sci Med Sci (2009) 1.55
Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am (2012) 1.54
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
Unnecessary drug use in frail older people at hospital discharge. J Am Geriatr Soc (2005) 1.54
Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ Couns (2002) 1.53
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
The relationships between sex hormones and sexual function in middle-aged and older European men. J Clin Endocrinol Metab (2011) 1.53
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum (2008) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
[The treatment of femoral neck fractures]. Tidsskr Nor Laegeforen (2010) 1.50
Walking speed predicts health status and hospital costs for frail elderly male veterans. J Rehabil Res Dev (2005) 1.48